# Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases

> **NCT01337440** · PHASE4 · UNKNOWN · sponsor: **Kanazawa University** · enrollment: 20 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Chronic Liver Disease

## Interventions

- **DRUG:** UDCA
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT01337440
- **Lead sponsor:** Kanazawa University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-04
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2011-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01337440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01337440, "Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01337440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*